Calmune will use the SEBVI platform to identify potent, high-affinity mAbs against a particular target.
Calmune and Crucell inked a deal focusing on research, development, production, and marketing of vaccines, proteins, and antibodies that prevent and/or treat infectious diseases. Calmune will use its SEBVI™ technology to prepare a panel of potent, high-affinity human mAbs against a predefined target.
Crucell will have the option to exclusively license these mAbs for further evaluation and development. Calmune will receive payments from Crucell at different stages of the discovery and development process as well as a royalty on sales of products that incorporate antibodies generated by Calmune.
SEBVI reportedly allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.
